← Back to patent-cliff list
Soficitinib
Tier C — Watch / tradeSoficitinib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TYK2
Indications (approved)：Chronic urticaria, Vitiligo, Atopic dermatitis, Plaque psoriasis, 结节性痒疹, Hepatic function decline, Urticaria, Psoriasis
Regional status
US
Phase I
2024-06-11
EU
-
China
Phase III
2024-11-14
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Soficitinib?
Approved indications include: Chronic urticaria, Vitiligo, Atopic dermatitis, Plaque psoriasis, 结节性痒疹, Hepatic function decline, Urticaria, Psoriasis.
When does the Soficitinib patent expire?
No public expiry year is available for Soficitinib yet; this page updates once verified.
How do I get a quote for Soficitinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01